Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAB LA + RPV LA in Viremic Participants Living With HIV-1
NCT06694805Phase 3Active, not recruiting
- Sponsor
- ViiV Healthcare
- Start
- Dec 2024
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 3, randomised, open-label trial of cabotegravir and rilpivirine in human immunodeficiency virus infection (HIV) (2 arms), sponsored by ViiV Healthcare. Primary endpoint: Number of participants with virologic suppression at 6 months. Started Dec 2024; status: active, not recruiting.
02
Drugs
cabotegravirrilpivirine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT06694805.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06694805.